Virginia Cancer Specialists, Pc

Arlington, Virginia 22205

4 studies enrolling now · 13 studies all time

What they study most

Biliary Tract Neoplasms, Breast Cancer, Breast Neoplasms, Cancer, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Adenocarcinoma, Gastroesophageal Junction Cancer, Gastrointestinal Diseases

Studies at this site

• Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer — Recruiting now
• Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer — Recruiting now
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer — Recruiting now
• Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors — Recruiting now
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations — Running, not enrolling
• Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). — Completed
• Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) — Stopped early
• Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) — Completed
• The Circulating Cell-free Genome Atlas Study — Status unconfirmed
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC) — Completed
• Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer — Completed
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed